FRANKLIN LAKES, N.J.,
Oct. 22, 2020 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced the appointment of
Patrick Kaltenbach as executive vice
president and chief technology officer, and the promotion of
Dave Hickey to executive vice
president and president, Life Sciences segment, both effective
January 1, 2021.
Kaltenbach, 57, will be responsible for continuing to drive the
company's category innovation strategy and leading all research and
development (R&D) activities, including executing the current
innovation pipeline and developing the future product
portfolio.
"Patrick has distinguished himself throughout nearly three
decades in R&D management and business leadership, making him
an ideal candidate to continue our drive toward category innovation
in alignment with our strategy to Grow, Simplify, and Empower,"
said Tom Polen, CEO and president of
BD. "In his time at BD, Patrick has been a thoughtful and
enterprising leader, bringing a strong external orientation to help
inform our strategy and best position BD to drive growth. He has
done outstanding work accelerating the R&D pipeline and
unlocking value in the Life Sciences segment, most recently working
to ensure our Life Sciences team was well positioned to support the
world's response to COVID-19 through a portfolio of innovative
diagnostics solutions."
Kaltenbach joined BD as president of the Life Sciences segment
in May 2018, after serving as senior
vice president of Agilent and president of their Life Sciences and
Applied Markets Group, where he was directly responsible for the
majority of Agilent's instrumentation and software portfolio.
Previously, Kaltenbach steered Agilent's largest R&D group,
directing all aspects of R&D strategy and leading teams of
engineers and scientists across multiple sites. He started his
career in R&D as an engineer with Hewlett-Packard Co., where he
went on to hold multiple senior management roles in R&D.
Kaltenbach holds an advanced degree in Precision Engineering from
Karlsruhe University of Applied
Sciences in Karlsruhe, Germany.
As CTO, Kaltenbach will also oversee the company's recently
launched "Innovation and Growth Fund" to advance BD's strategy and
increase investments in priority R&D programs that accelerate
growth.
John DeFord to retire
Kaltenbach succeeds John DeFord
in the chief technology officer role. DeFord, who joined BD through
the 2017 acquisition of C. R. Bard, Inc., recently announced his
intention to retire at the end of the calendar year.
"John's impact over his 35-year career goes well beyond 'what'
he delivered, but 'how' he did it: With a deep understanding of our
customers and their challenges and an unwavering commitment to
quality, talent development, and inclusion and diversity," said
Polen. "We are thankful for his countless accomplishments and the
significant impact he's made at BD and throughout patient care
around the world."
DeFord will continue to serve as an advisor and technical and
scientific consultant for BD upon his retirement.
Dave Hickey promoted to
executive vice president and president, Life Sciences
segment
Succeeding Kaltenbach as executive vice president and president
of the Life Sciences segment is Dave
Hickey, 57, who currently serves as worldwide president of
the Integrated Diagnostics Solutions business. As president of the
Life Sciences segment, Hickey will oversee the Biosciences,
Preanalytical Systems and Diagnostics Systems businesses
worldwide.
"I'm confident Dave is the right successor to lead the Life
Sciences segment at this critical time for the industry and for
public health," said Polen. "Throughout nearly 30 years of
experience in the life sciences field, Dave has consistently
delivered high performance and he has proven himself as an
empathetic, passionate and transformative leader of
customer-centric teams. Dave's leadership in the Diagnostics space
has been on full display during the pandemic, as his team rallied
around our purpose and delivered innovative laboratory and
point-of-care COVID-19 testing solutions in record time."
Hickey joined BD in 2014 as vice president and general manager
for the Clinical Microbiology business and was promoted to
president of the Diagnostics Systems business in 2016. Prior to BD,
Hickey spent 22 years with Siemens Healthcare Diagnostics in
multiple positions of increasing responsibility. Hickey began his
career as a clinical biochemist in the United Kingdom.
Both Kaltenbach and Hickey will report to Polen.
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of health care by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for health
care providers. BD and its 65,000 employees have a passion and
commitment to help enhance the safety and efficiency of clinicians'
care delivery process, enable laboratory scientists to accurately
detect disease and advance researchers' capabilities to develop the
next generation of diagnostics and therapeutics. BD has a presence
in virtually every country and partners with organizations around
the world to address some of the most challenging global health
issues. By working in close collaboration with customers, BD can
help enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. For more information on
BD, please visit bd.com.
Contacts:
|
|
Kristen
Cardillo
|
Kristen M. Stewart,
CFA
|
BD Public
Relations
|
BD Investor
Relations
|
201.847.5657
|
845.642.1256
|
Kristen.Cardillo@bd.com
|
Kristen.Stewart@bd.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bd-announces-executive-leadership-appointments-301157727.html
SOURCE BD (Becton, Dickinson and Company)